MGMT and neoplasm: There was no significant association between the methylation status of any of the ELMO promoter CpG islands and any of the examined clinical characteristics, including age, gender, WHO performance status, diagnosis, use of corticosteroids at treatment start, multifocal disease, tumor brain location, site of relapse tumor, or MGMT promoter methylation.